reports
Crown Castle Reports First Quarter 2025 Results and Maintains Outlook ...
Crown Castle Reports First Quarter 2025 Results and Maintains Outlook for Full Year 2025 HOUSTON, April 30, 2025 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) ("Crown Castle") today reported results for the first quarter ended March 31, 2025 and maintains its full year 2025 Outlook, as reflected in the table below. (dollars in millions, except per share amounts)Current Full Year 2025 Outlook Midpoint(a) Full Year 2024 Actual Change % ChangeSite rental revenues(b)$4,010 $4,268 $(258) (6)%Net income (loss)$205 $(3,903) $4,108 N/ANet income (loss) per share—diluted$0.47 $(8.98) $9.45 N/A...
United Rentals Inc: 2 directors
Two Directors at United Rentals Inc sold 5,549 shares at between 626.280USD and 633.104USD. The significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
Esperion to Participate in The Citizens Life Sciences Conference
Esperion to Participate in The Citizens Life Sciences Conference ANN ARBOR, Mich., April 25, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted Citizens Life Sciences Conference on May 8, 2025, at 12:30 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. ...
Esperion Unveils Promising Research Supporting Lead Development Candid...
Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025 – Expands Development Portfolio with Introduction of a Novel Program Targeting PSC – – Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across Multiple PSC-Relevant Pre-Clinical Models – – Demonstrates Internal R&D Capabilities with Wholly Owned, Next-Generation Candidates Targeting Liver and Kidney Disease – – Esperion to Webcast R&D Day Event Today at 9:00 a.m. ET – ANN ARBOR, Mich., April 24, 202...
Esperion to Report First Quarter 2025 Financial Results on May 6
Esperion to Report First Quarter 2025 Financial Results on May 6 ANN ARBOR, Mich., April 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after completion of the call and will b...
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovat...
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025 Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases ANN ARBOR, Mich., April 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it will host an in-person R&D Day for analysts and investors on April 24, 2025, beginning at 9:00 a.m. ET in New York City. This event will feature presentations from company leadership and key opinion leaders to provide a deep dive int...
Crown Castle Announces First Quarter 2025 Earnings Conference Call Det...
Crown Castle Announces First Quarter 2025 Earnings Conference Call Details HOUSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) ("Crown Castle") plans to release its first quarter 2025 results on Wednesday, April 30, 2025, after the market closes. In conjunction with the release, Crown Castle has scheduled a conference call for Wednesday, April 30, 2025, at 5:00 p.m. eastern time. A listen only live audio webcast of the conference call, along with any supplemental materials, can be accessed on the Crown Castle website at . Participants may join the conference call by...
Esperion Appoints Robert E. Hoffman to Board of Directors
Esperion Appoints Robert E. Hoffman to Board of Directors - Veteran Industry Executive Brings Decades of Financial and Leadership Experience - ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Robert E. Hoffman as an independent director, effective immediately, and he will also serve as Chairperson of the Audit Committee effective May 29, 2025. In addition, the Company announced that Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D. Phil. will step down from the board of directors, effective June 1, 2025. “We are pleased to ...
Crown Castle Announces CEO Transition
Crown Castle Announces CEO Transition Daniel Schlanger, Current Executive Vice President and CFO, Appointed Interim President and CEO Search Underway to Identify Successor CEO Reaffirms All Recently Announced Financial Guidance and Capital Allocation Policies Highly Confident in Value-Maximizing Transformation into a Pure-Play US Tower Company HOUSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) (“Company” or “Crown Castle”) today announced that the Company’s Board of Directors (Board) has appointed Dan Schlanger, Executive...
Esperion to Participate in 24th Annual Needham Virtual Healthcare Conf...
Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference ANN ARBOR, Mich., March 24, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, at 8:45 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion Therapeutic...
Esperion Aligns with U.S. Food and Drug Administration to Initiate Pha...
Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia – Confirms Sufficient Data to Complete Phase 2 Clinical Study Enrollment and Advance to Phase 3 Studies in Both Heterozygous and Homozygous Familial Hypercholesterolemia – – Establishes Pediatric Path Forward to Start and Complete Phase 3 Trial and Secure Additional Six-Month Patent Extension Through June 2031 – ANN ARBOR, Mich., March 20, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that f...
Moody's Ratings affirms Crown Castle Inc.'s Baa3 ratings, changes outl...
Moody's Ratings (Moody's) today affirmed Crown Castle Inc.'s ("Crown Castle" or the "the REIT") Baa3 senior unsecured debt rating and changed the outlook to negative from stable. In the same rating action, we affirmed the REIT's Prime-3 commercial paper (CP) rating, (P)Baa3 senior unsecured shelf ra...
Crown Castle Appoints Katherine Motlagh to its Board of Directors
Crown Castle Appoints Katherine Motlagh to its Board of Directors HOUSTON, March 17, 2025 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) ("Crown Castle") announced today the appointment of Katherine Motlagh to its board of directors. Ms. Motlagh’s appointment is effective today, March 17, 2025. Ms. Motlagh previously served as CFO of CyrusOne LLC and CFO of the Europe, Africa and Latin America regions of American Tower Corporation. She currently serves on the board of directors of EVgo, Inc., where she serves as Chair of the audit committee. “Katherine brings extensive financial, inv...
Crown Castle Names Sunit Patel as Chief Financial Officer
Crown Castle Names Sunit Patel as Chief Financial Officer HOUSTON, March 17, 2025 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) ("Crown Castle") announced today the appointment of Sunit Patel to the position of Executive Vice President and Chief Financial Officer (CFO), effective April 1, 2025. Mr. Patel will be leaving his position on Crown Castle’s Board of Directors, effective March 17, 2025. "We look forward to welcoming Sunit Patel to the Crown Castle team,” said Steven Moskowitz, Crown Castle's Chief Executive Officer. "Sunit brings unique, extensive telecommunications industry...
Moody's affirms Crown Castle Inc.'s Baa3 ratings, changes outlook to n...
Moody's Ratings (Moody's) today affirmed Crown Castle Inc.'s ("Crown Castle" or the "the REIT") Baa3 senior unsecured debt rating and changed the outlook to negative from stable. In the same rating action, we affirmed the REIT's Prime-3 commercial paper (CP) rating, (P)Baa3 senior unsecured shelf ra...
Crown Castle Announces Agreement To Sell Fiber Segment to EQT and Zayo...
Crown Castle Announces Agreement To Sell Fiber Segment to EQT and Zayo, Reports Fourth Quarter and Full Year 2024 Results, and Provides Outlook for Full Year 2025 Successfully Concludes Strategic Review with Agreement to Sell Small Cells and Fiber Solutions for $8.5 Billion Results in Crown Castle as the Only Pure-Play, Publicly-Traded US Tower Company Increases Capital Efficiency with Updated Capital Allocation Framework, Including Anticipated New Dividend Policy and Proposed Approximately $3.0 Billion Share Repurchase Program HOUSTON, March 13, 2025 (GLOBE NEWSWIRE) -- Crown Castle I...
Crown Castle Announces Updated Fourth Quarter 2024 Earnings Conference...
Crown Castle Announces Updated Fourth Quarter 2024 Earnings Conference Call Details HOUSTON, March 12, 2025 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) ("Crown Castle") plans to reschedule the release of its fourth quarter 2024 results to Thursday, March 13, 2025, after the market closes. As previously disclosed, Crown Castle is pursuing a review of strategic alternatives that may be available with respect to its Fiber segment. Due to the significant demands related to the strategic review, Crown Castle has rescheduled its conference call for Thursday, March 13, 2025 at 5:00 p.m. ea...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of United Rentals (North America), Inc. (UNRA) and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 6 March 2025 in which we reassessed the appropriateness of the ...
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results – FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million – –Q4 Total Revenue Grew 114% Y/Y to $69.1 Million; Q4 U.S. Net Product Revenue Grew 52% Y/Y to $31.6 Million – – Q4 Retail Prescription Equivalents Grew 45% Y/Y and 12% Q/Q – – Focused On Three Pillars for Building a Blockbuster Company: Continued Revenue Growth, Reaching Operating Profitability, and Portfolio Expansion/Pipeline Advancement – – Announces Development of Trip...
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedo...
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia – Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales – ANN ARBOR, Mich., March 03, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with CSL Seqirus (ASX:CSL) for the exclusive rights to commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia and New Zealan...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.